The Drug Trade

By Ryan Kelly, Randy Leonard and Sean McMinn

While most drugs’ prices move slowly and predictably, some companies live on the margins. Valeant Pharmaceuticals, whose drugs dominate our list of price hikes, is under federal investigation for its pricing practices. Research costs aren’t to blame: Valeant spends only 3 percent of its revenue on R&D (Pfizer and Merck spend 16.9 percent), preferring to acquire existing drugs and promptly raise prices.

Search our database, which tracks the pricing data collected by the Centers for Medicare & Medicaid Services, to see how the prices of individual drugs have changed since 2013.

Sorry, this CQ app is not supported on mobile devices. This is a preview of what you can see on your desktop computer.